An ultrasonic medicine penetration treatment device for nephrology department

Abstract

The application relates to the technical field of ultrasonic treatment equipment, and relates to an ultrasonic medicine transmission treatment device for a nephrology department, which comprises a device body, a medicine bearing assembly and a limiting and adhering driving assembly. The device body is provided with an ultrasonic wave generating structure for emitting ultrasonic waves towards a patient; the medicine bearing assembly is assembled on the device body; one end of the medicine bearing assembly towards the patient is a medicine bearing end for mounting a medicine pad; the other end of the medicine bearing assembly opposite to the medicine bearing end is an ultrasonic wave transmission end which is adhered to the emitting surface of the ultrasonic wave generating structure and is used for receiving ultrasonic waves and transmitting the ultrasonic waves to the medicine bearing end; the limiting and adhering driving assembly is assembled on the device body and is in transmission connection with the medicine bearing assembly; the limiting and adhering driving assembly is used for applying a driving force towards the ultrasonic wave generating structure to the medicine bearing assembly so that the ultrasonic wave transmission end is kept adhered to the emitting surface of the ultrasonic wave generating structure. The stability of the treatment effect is improved.

Description

Technical Field

[0001] This invention relates to the field of ultrasound therapy equipment technology, and in particular to an ultrasound transdermal drug delivery device for nephrology. Background Technology

[0002] The nephrology ultrasound transdermal drug delivery device is a non-invasive medical device that uses the physical effect of ultrasound to promote drug penetration through the skin and is used as an adjunct treatment for kidney diseases.

[0003] In existing nephrology ultrasound-guided drug delivery devices, the drug carrier is usually placed directly between the emitting surface of the ultrasound treatment head and the patient's skin in the kidney area. The drug carrier is fixed by the clamping force between the treatment head and the skin. The main unit drives the treatment head to emit ultrasound waves, and the physical effect of ultrasound waves promotes drug penetration into the body through the skin. During the treatment, ultrasound vibration, changes in the patient's position, or the flow of coupling agent can easily cause the drug carrier to shift relative to the treatment head. Furthermore, the adhesion between the two can easily fail, forming air gaps. This prevents the ultrasound waves from effectively transmitting to the drug, resulting in insufficient drug release and ultimately reducing the stability of the treatment effect. Summary of the Invention

[0004] In order to overcome the shortcomings of the prior art, the purpose of this invention is to provide an ultrasound transdermal drug delivery device for nephrology, which improves the stability of the treatment effect.

[0005] The objective of this invention is achieved through the following technical solution:

[0006] A nephrology ultrasound-guided drug delivery device includes:

[0007] The device body is provided with an ultrasonic wave generating structure, which is used to emit ultrasonic waves toward the patient.

[0008] A drug-carrying assembly is assembled on the device body; the end of the drug-carrying assembly facing the patient is the drug-carrying end, which is used to install a medicated pad; the end of the drug-carrying assembly opposite to the drug-carrying end is the ultrasonic wave transmission end, which is in contact with the emitting surface of the ultrasonic wave generating structure, and is used to receive ultrasonic waves and transmit ultrasonic waves to the drug-carrying end.

[0009] A limiting and fitting drive assembly is assembled on the device body and is connected to the drug carrier assembly. The limiting and fitting drive assembly is used to apply a driving force toward the ultrasonic wave generating structure to the drug carrier assembly so that the ultrasonic wave transmission end is kept in contact with the emitting surface of the ultrasonic wave generating structure.

[0010] Furthermore, the device body has an installation cavity located at the end of the device body facing the patient; the ultrasonic wave generating structure is installed at the bottom of the installation cavity and is used to emit multi-focal ultrasonic waves in the direction facing the patient.

[0011] The device body has a limiting groove at the end facing the patient, and the limiting groove is arranged around the outer periphery of the ultrasonic wave generating structure along the circumference of the device body; the drug carrier component is detachably embedded in the limiting groove, and the ultrasonic wave transmitting end is synchronously attached to the emitting surface of the ultrasonic wave generating structure as the drug carrier component docks.

[0012] Furthermore, the outer wall of the limiting groove is provided with a plurality of vent holes, each of which is arranged at intervals along the circumference of the limiting groove and penetrates both the outer wall and the inner wall of the limiting groove.

[0013] Furthermore, the device body includes a mounting base and a sealing base; the mounting cavity is formed in the mounting base and extends through the end of the mounting base away from the patient; the cavity wall of the mounting cavity is provided with internal threads; the limiting groove is formed at the end of the mounting base facing the patient;

[0014] A sealing element mounting groove is provided at the bottom of the mounting cavity, and the sealing element mounting groove is arranged around the circumference of the mounting cavity;

[0015] The outer circumferential surface of the sealing seat is provided with an external thread, which is used to engage with the internal thread of the mounting cavity to seal the mounting cavity; the bottom end of the sealing seat presses against the sealing element in the sealing element mounting groove simultaneously as the external thread engages with the internal thread.

[0016] Furthermore, the ultrasonic wave generating structure has multiple ultrasonic array elements, each of which is arranged at intervals along the circumference of the mounting cavity; each ultrasonic array element has multiple piezoelectric elements, and the multiple piezoelectric elements of the same ultrasonic array element are arranged at intervals along the radial direction of the mounting cavity; among the multiple ultrasonic array elements, the multiple piezoelectric elements located at the same radial position in the mounting cavity together form an ultrasonic focusing group; multiple ultrasonic focusing groups at different radial positions are respectively used to form ultrasonic focusing areas at corresponding depths within human tissue;

[0017] The bottom end of the sealing seat is provided with an excitation part corresponding to each of the ultrasonic focusing groups. Each of the excitation parts is assembled with the sealing seat and the mounting seat and is electrically connected to each of the piezoelectric array elements corresponding to the ultrasonic focusing group.

[0018] The device body is also provided with a control unit, which is assembled on the sealing seat and electrically connected to each of the excitation parts.

[0019] Furthermore, the outer peripheral surface of the mounting base is provided with multiple first anti-detachment grooves, the multiple first anti-detachment grooves are arranged at intervals along the circumference of the mounting base, and all of them penetrate the two ends of the mounting base facing the patient and away from the patient along the depth direction of the limiting groove.

[0020] The drug carrier assembly is provided with a plurality of first plug-in portions, which are arranged at intervals along the circumference of the drug carrier assembly and cooperate with the corresponding first anti-dislodgement plug-in portions, and protrude from the end of the mounting base away from the patient; the drug carrier assembly is embedded into the limiting groove as each of the first plug-in portions is plugged in.

[0021] Furthermore, the drug-carrying assembly includes a carrier seat and a clamping seat; the two opposite ends of the carrier seat are the ultrasonic transmission end and the drug-carrying end, respectively; each of the first insertion parts is disposed on the outer peripheral surface of the carrier seat, and the carrier seat is embedded in the limiting groove as each of the first insertion parts is inserted;

[0022] The outer peripheral surface of the mounting base is provided with multiple second anti-dislodgement grooves. Each second anti-dislodgement groove is arranged at intervals along the circumference of the mounting base and penetrates the end of the mounting base facing the patient along the depth direction of the limiting groove.

[0023] The clamping seat is slidably sleeved on the outer peripheral surface of the support seat. The clamping seat is used to abut against the outer peripheral edge of the medicated pad applied to the drug support end. The clamping seat is provided with a plurality of second insertion parts, each of the second insertion parts being inserted into and engaged with the corresponding second anti-dislodgement groove. The clamping seat abuts against the outer peripheral edge of the medicated pad synchronously with the insertion action of the second insertion parts.

[0024] Furthermore, a plurality of second anti-detachment grooves are provided in a one-to-one correspondence with a plurality of first anti-detachment grooves, and each second anti-detachment groove is connected to the corresponding first anti-detachment groove.

[0025] The first insertion part has a card supply groove on the side facing the second anti-disengagement groove; the second insertion part has an elastic locking member on the side facing the first anti-disengagement groove; the elastic locking member engages with the corresponding card supply groove as the second insertion part is inserted.

[0026] The limiting fit drive assembly is assembled on the sealing seat and is respectively connected to each of the first insertion parts.

[0027] Furthermore, each of the first insertion portions is provided with a force-bearing groove and a clearance groove; each of the force-bearing grooves passes through the corresponding first insertion portion along the radial direction of the mounting base; the clearance groove extends along the circumference of the mounting base and passes through one side of the corresponding first insertion portion; the clearance groove and the force-bearing groove are arranged sequentially in the direction away from the patient and are interconnected.

[0028] The limiting and fitting drive assembly includes a rotary seat, an elastic drive member, and a transmission seat; the rotary seat is rotatably embedded in the end of the sealing seat away from the external thread; the transmission seat is movably sleeved on the outer peripheral surface of the sealing seat; the outer peripheral surface of the transmission seat is provided with a force-applying part corresponding to each of the force-receiving grooves, and the force-applying part moves with the rotation of the transmission seat and is embedded in the corresponding clearance groove;

[0029] The elastic drive member is sleeved on the outer peripheral surface of the sealing seat, and the two ends of the elastic drive member are respectively assembled to the rotary seat and the transmission seat. The elastic drive member is used to drive the transmission seat to move away from the patient, so that each of the force-applying parts is embedded in the corresponding force-receiving groove, so as to apply a contact force to the bearing seat to keep the ultrasonic transmission end and the emitting surface of the ultrasonic generation structure in contact.

[0030] Furthermore, the transmission seat is provided with multiple anti-torsion limiting rods and multiple anti-slip teeth; the multiple anti-torsion limiting rods all extend in a direction away from the bearing seat and are arranged at intervals along the circumference of the transmission seat; the rotary seat is provided with multiple force-bearing through holes, and each of the anti-torsion limiting rods is slidably inserted into the corresponding force-bearing through hole, and the anti-torsion limiting rods are used to drive the rotary seat to rotate synchronously with the transmission seat; each of the anti-slip teeth is arranged at the end of the transmission seat away from the patient and is arranged at intervals along the circumference of the transmission seat.

[0031] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0032] The device body is equipped with an ultrasonic wave generating structure, which is used to emit ultrasonic waves toward the patient; thereby providing the necessary physical driving force for transdermal drug penetration and laying a stable energy foundation for the ultrasonic transdermal drug delivery treatment process.

[0033] The drug-carrying component is assembled onto the device body; the end of the drug-carrying component facing the patient is the drug-carrying end, which is used to install the medicated pad; the end of the drug-carrying component opposite to the drug-carrying end is the ultrasonic wave transmission end, which is in contact with the emitting surface of the ultrasonic wave generating structure, and is used to receive ultrasonic waves and transmit ultrasonic waves to the drug-carrying end; thus, the installation and positioning of the medicated pad are achieved through the independent drug-carrying component, keeping the medicated pad and the drug-carrying component relatively fixed, and preventing displacement of the medicated pad relative to the emitting surface of the ultrasonic wave generating structure; a continuous ultrasonic energy conduction path is constructed through the ultrasonic wave transmission end, reducing the dispersion and loss of ultrasonic energy during transmission, so that the medicated pad area can obtain uniform ultrasonic energy.

[0034] The limiting and fitting drive assembly is assembled on the device body and is connected to the drug-carrying assembly. The limiting and fitting drive assembly is used to apply a driving force toward the ultrasonic wave generating structure to the drug-carrying assembly so that the ultrasonic wave transmission end is kept in contact with the emitting surface of the ultrasonic wave generating structure. In this way, the continuous driving force counteracts the interference caused by ultrasonic vibration, patient position changes and coupling agent flow during treatment, reduces the probability of relative displacement and air gap formation between the ultrasonic wave transmission end and the emitting surface of the ultrasonic wave generating structure, and ensures that ultrasonic energy can be continuously and stably transmitted to the drug-carrying assembly, thereby improving the stability of the treatment effect.

[0035] The coordinated operation of the drug-carrying component and the limiting and adhering drive component enables the fixation of the medicated pad position and the stable maintenance of the ultrasonic energy transmission interface. The drug-carrying component provides a stable mounting carrier for the medicated pad, while the limiting and adhering drive component provides continuous adhesion force to the drug-carrying component. This reduces the risk of overlapping medicated pad displacement and ultrasonic energy transmission interruption during treatment, ensuring a high degree of synchronicity between the drug penetration process and the ultrasonic energy action process, and further improving the stability of the treatment effect. Attached Figure Description

[0036] Figure 1 This is a three-dimensional structural diagram of an ultrasonic transdermal drug delivery device for nephrology according to the present invention, wherein the device body and the drug delivery component are separated.

[0037] Figure 2 for Figure 1 A magnified view of a portion of point A in the middle;

[0038] Figure 3 for Figure 1 Schematic diagram of the middle mounting base;

[0039] Figure 4 for Figure 1 A schematic diagram showing the fit between the mounting base and the sealing seat;

[0040] Figure 5 for Figure 1 Assembly diagram of the central device body, drug delivery component, and limiting and fitting drive component;

[0041] Figure 6 for Figure 5 A magnified view of a portion of point B in the middle.

[0042] In the diagram: 1. Device body; 11. Ultrasonic generating structure; 111. Ultrasonic array element group; 1111. Piezoelectric array element; 12. Mounting cavity; 121. Internal thread; 122. Seal mounting groove; 13. Limiting groove; 131. Vent hole; 14. Mounting seat; 141. First anti-detachment groove; 142. Second anti-detachment groove; 143. Strap insertion seat; 15. Sealing seat; 151. External thread; 152. Excitation part; 16. Control unit; 2. Drug carrier assembly ; 21. Drug carrier end; 22. Ultrasonic transmission end; 23. First insertion part; 231. Card insertion groove; 232. Force receiving groove; 233. Clearance groove; 24. Bearing seat; 25. Pressing seat; 251. Second insertion part; 2511. Elastic locking element; 3. Limiting and fitting drive assembly; 31. Rotary seat; 311. Force receiving through hole; 32. Elastic drive element; 33. Transmission seat; 331. Force application part; 332. Anti-torsion limiting rod; 333. Anti-slip tooth. Detailed Implementation

[0043] The present invention will now be further described in conjunction with the accompanying drawings and specific embodiments. It should be noted that, without conflict, the various embodiments or technical features described below can be arbitrarily combined to form new embodiments.

[0044] It should be noted that when an element is described as being "fixed to" another element, it can be directly attached to the other element or there may be an intervening element. When an element is described as being "connected to" another element, it can be directly connected to the other element or there may be an intervening element. The terms "vertical," "horizontal," "left," "right," and similar expressions used herein are for illustrative purposes only and do not represent the only possible implementations.

[0045] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. The term "and / or" as used herein includes any and all combinations of one or more of the associated listed items.

[0046] See Figure 1 , Figure 5The specific implementation of a preferred embodiment of the present invention is as follows: a nephrology ultrasound transdermal drug delivery device includes: a device body 1, a drug delivery component 2, and a limiting and fitting drive component 3.

[0047] The device body 1 is provided with an ultrasonic wave generating structure 11, which is used to emit ultrasonic waves toward the patient.

[0048] The drug-carrying component 2 is assembled on the device body 1; the end of the drug-carrying component 2 facing the patient is the drug-carrying end 21, which is used to install the medicated pad; the end of the drug-carrying component 2 opposite to the drug-carrying end 21 is the ultrasonic wave transmission end 22, which is in contact with the emitting surface of the ultrasonic wave generating structure 11, and is used to receive ultrasonic waves and transmit ultrasonic waves to the drug-carrying end 21.

[0049] The limiting and fitting drive assembly 3 is assembled on the device body 1 and is connected to the drug carrier assembly 2 in a transmission manner. The limiting and fitting drive assembly 3 is used to apply a driving force toward the ultrasonic wave generating structure 11 to the drug carrier assembly 2 so that the ultrasonic wave transmitting end 22 is kept in contact with the emitting surface of the ultrasonic wave generating structure 11.

[0050] In use, first, install the medicated pad on the medicated end 21 of the medicated carrier component 2; then assemble the medicated carrier component 2 onto the device body 1, so that the ultrasonic transmission end 22 of the medicated carrier component 2 is initially attached to the emitting surface of the ultrasonic generating structure 11 of the device body 1; then connect the output end of the limiting and attaching drive component 3 to the medicated carrier component 2, so that the limiting and attaching drive component 3 applies a driving force toward the ultrasonic generating structure 11 to the medicated carrier component 2, so that the ultrasonic transmission end 22 and the emitting surface of the ultrasonic generating structure 11 remain attached; next, place the device body 1 against the area of ​​the patient that needs treatment, such as the skin position corresponding to the kidneys in the waist, keeping the device body 1 relatively stable with the patient's skin; finally, activate the ultrasonic generating structure 11, so that the ultrasonic generating structure 11 emits ultrasonic waves toward the patient, and the ultrasonic waves are transmitted to the medicated end 21 through the ultrasonic transmission end 22, acting on the medicated pad and the patient's skin to perform ultrasonic transdermal drug delivery therapy.

[0051] Obviously, the device body 1 is equipped with an ultrasonic wave generating structure 11, which is used to emit ultrasonic waves in the direction toward the patient; thereby providing the necessary physical driving force for drug percutaneous penetration and laying a stable energy foundation for the ultrasonic transdermal drug delivery treatment process.

[0052] The drug-carrying component 2 is assembled on the device body 1. The end of the drug-carrying component 2 facing the patient is the drug-carrying end 21, which is used to mount the medicated pad. The end of the drug-carrying component 2 opposite to the drug-carrying end 21 is the ultrasonic transmission end 22, which is in contact with the emitting surface of the ultrasonic wave generating structure 11. The ultrasonic transmission end 22 is used to receive ultrasonic waves and transmit them to the drug-carrying end 21. Thus, the independent drug-carrying component 2 enables the installation and positioning of the medicated pad, keeping the medicated pad and the drug-carrying component 2 relatively fixed and preventing displacement of the medicated pad relative to the emitting surface of the ultrasonic wave generating structure 11. The ultrasonic transmission end 22 constructs a continuous ultrasonic energy conduction path, reducing the dispersion and loss of ultrasonic energy during transmission, allowing the medicated pad area to receive uniform ultrasonic energy. The limiting and fitting drive component 3 is assembled on the device body 1 and is connected to the drug-carrying component 2. The limiting and fitting drive component 3 is used to transmit ultrasonic waves to the drug-carrying end 21. The drug-carrying component 2 applies a driving force toward the ultrasonic wave generating structure 11 to keep the ultrasonic wave transmitting end 22 in contact with the emitting surface of the ultrasonic wave generating structure 11. This continuous driving force counteracts interference from ultrasonic vibrations, patient position changes, and coupling agent flow during treatment, reducing the probability of relative displacement and air gap formation between the ultrasonic wave transmitting end 22 and the emitting surface of the ultrasonic wave generating structure 11. This ensures that ultrasonic energy is continuously and stably transmitted to the drug-carrying component 2, thereby improving the stability of the treatment effect. Based on the synergistic cooperation between the drug-carrying component 2 and the limiting and adhering driving component 3, the position of the medicated pad is fixed, and the ultrasonic energy transmission interface is stably maintained. The drug-carrying component 2 provides a stable mounting carrier for the medicated pad, while the limiting and adhering driving component 3 provides a continuous adhering force, reducing the risk of overlapping medicated pad displacement and ultrasonic energy transmission interruption during treatment. This ensures a high degree of synchronicity between the drug penetration process and the ultrasonic energy action process, further improving the stability of the treatment effect.

[0053] See Figures 1-3 In this embodiment, in order to more effectively improve the stability of the treatment effect, preferably, the device body 1 has an installation cavity 12, which is located at the end of the device body 1 facing the patient; the ultrasonic wave generating structure 11 is installed at the bottom of the installation cavity 12, and the ultrasonic wave generating structure 11 is used to emit multi-focal ultrasonic waves in the direction towards the patient.

[0054] The device body 1 has a limiting groove 13 at the end facing the patient, and the limiting groove 13 is arranged around the outer periphery of the ultrasonic wave generating structure 11 along the circumference of the device body 1; the drug carrier component 2 is detachably embedded in the limiting groove 13, and the ultrasonic wave transmitting end 22 is synchronously attached to the emitting surface of the ultrasonic wave generating structure 11 as the drug carrier component 2 docks.

[0055] The mounting cavity 12 provides a mounting reference for the ultrasonic wave generating structure 11, preventing the ultrasonic wave generating structure 11 from shifting or loosening during high-frequency vibration, ensuring that the emission frequency, amplitude, and propagation direction of the ultrasonic waves remain stable, and reducing fluctuations and distortions in ultrasonic energy. The limiting groove 13 pre-positions the drug carrier component 2, ensuring the consistency of the position of the drug carrier component 2 during each assembly, so that the ultrasonic wave transmitting end 22 can be effectively aligned with the emitting surface of the ultrasonic wave generating structure 11, ensuring that ultrasonic energy can be effectively transmitted to the drug carrier component 2. By using multi-focal-band ultrasonic waves to simultaneously generate cavitation and microfluidic effects at different depths in human tissue, not only can the treatment coverage be expanded, but drug molecules can also be continuously driven to penetrate deep into the kidney tissue, increasing the penetration depth and the amount of drug per unit time.

[0056] Furthermore, the outer wall of the limiting groove 13 is provided with a plurality of exhaust holes 131, each of the exhaust holes 131 being arranged at intervals along the circumference of the limiting groove 13 and all penetrating the outer wall of the limiting groove 13 and the inner wall of the limiting groove 13.

[0057] The air remaining between the ultrasonic transmission end 22 and the emitting surface of the ultrasonic generating structure 11 during the process of embedding the drug carrier component 2 into the limiting groove 13 is discharged through the vent 131, which avoids the formation of an air gap when the two are attached; at the same time, it can reduce the resistance during the assembly of the drug carrier component 2, making the assembly process smoother and ensuring that the ultrasonic transmission end 22 and the emitting surface can be tightly attached.

[0058] See Figure 1 , Figure 4 Furthermore, the device body 1 includes a mounting base 14 and a sealing base 15; the mounting cavity 12 is opened in the mounting base 14 and passes through the end of the mounting base 14 away from the patient; the cavity wall of the mounting cavity 12 is provided with an internal thread 121; the limiting groove 13 is opened in the end of the mounting base 14 facing the patient;

[0059] The bottom of the mounting cavity 12 is provided with a sealing element mounting groove 122, which surrounds the mounting cavity 12 circumferentially;

[0060] The outer circumferential surface of the sealing seat 15 is provided with an external thread 151, which is used to engage with the internal thread 121 of the mounting cavity 12 to seal the mounting cavity 12; the bottom end of the sealing seat 15 presses against the sealing element in the sealing element mounting groove 122 simultaneously as the external thread 151 engages with the internal thread 121.

[0061] The separate mounting base 14 and sealing base 15 structure facilitates the inspection and replacement of the ultrasonic generating structure 11 inside the mounting cavity 12. The sealing base 15 can be quickly disassembled and assembled through the threaded connection. At the same time, the axial force of the sealing base 15 during screwing automatically presses against the sealing element, so that the mounting cavity 12 can be sealed without the need for additional fastening structure, preventing coupling agent, sweat and other liquids from entering the mounting cavity 12 during treatment and damaging the relevant electronic components.

[0062] Preferably, the outer periphery of the mounting base 14 is symmetrically provided with strap insertion seats 143. The symmetrically arranged strap insertion seats 143 can be used to quickly assemble and fix the strap, so as to stably bind the device body 1 to the treatment site of the patient's kidney area in the waist.

[0063] Furthermore, the ultrasonic wave generating structure 11 has multiple ultrasonic array elements 111, each of which is arranged at intervals along the circumference of the mounting cavity 12; each ultrasonic array element 111 has multiple piezoelectric elements 1111, and the multiple piezoelectric elements 1111 of the same ultrasonic array element 111 are arranged at intervals along the radial direction of the mounting cavity 12; among the multiple ultrasonic array elements 111, the multiple piezoelectric elements 1111 located at the same radial position in the mounting cavity 12 together form an ultrasonic focusing group; multiple ultrasonic focusing groups at different radial positions are respectively used to form ultrasonic focusing areas at corresponding depths within human tissue.

[0064] The bottom end of the sealing seat 15 is provided with an excitation part 152 corresponding to each of the ultrasonic focusing groups. Each of the excitation parts 152 is assembled with the sealing seat 15 and the mounting seat 14 and is electrically connected to each of the piezoelectric array elements 1111 corresponding to the ultrasonic focusing group.

[0065] The device body 1 is also provided with a control unit 16, which is assembled on the sealing seat 15 and is electrically connected to each of the excitation parts 152.

[0066] Multi-focal-length ultrasonic effects are achieved by utilizing the acoustic characteristics of ultrasonic focusing groups at different radial positions, eliminating the need for complex phase modulation techniques. The automatic electrical connection between the excitation unit 152 and the piezoelectric array element 1111 when the sealing seat 15 is screwed on eliminates the need for separate wiring steps, simplifying the assembly process of the device. The control unit 16 drives each excitation unit 152 in a unified manner, ensuring that multiple piezoelectric array elements 1111 within the ultrasonic focusing group can emit ultrasonic waves synchronously, making the multi-focal-length ultrasonic field more uniform and stable.

[0067] The excitation part 152 is preferably an annular conductive spring corresponding to each ultrasonic focusing group, which can increase the effective contact area between the excitation part 152 and each piezoelectric element 1111 and avoid the problem of uneven contact resistance caused by single-point or multi-point discrete contact; at the same time, when the annular structure is screwed into the sealing seat 15, it can apply contact pressure evenly, ensuring that all piezoelectric elements 1111 in the same ultrasonic focusing group can obtain a stable and consistent electrical connection.

[0068] See Figure 1 , Figure 2 , Figure 5 and Figure 6 Furthermore, the outer peripheral surface of the mounting base 14 is provided with multiple first anti-detachment grooves 141. The multiple first anti-detachment grooves 141 are arranged at intervals along the circumference of the mounting base 14, and all of them penetrate the two ends of the mounting base 14 facing the patient and away from the patient along the depth direction of the limiting groove 13.

[0069] The drug carrier component 2 is provided with a plurality of first insertion parts 23, which are arranged at intervals along the circumference of the drug carrier component 2 and are inserted into the corresponding first anti-dislodgement groove 141, and protrude from the end of the mounting base 14 away from the patient; the drug carrier component 2 is embedded into the limiting groove 13 as each of the first insertion parts 23 is inserted.

[0070] The insertion and engagement of the first connector 23 with the first anti-detachment groove 141 provides circumferential positioning of the drug carrier assembly 2, preventing it from rotating during treatment. Simultaneously, the guiding function of the first anti-detachment groove 141 ensures the drug carrier assembly 2 is stably embedded in the limiting groove 13, preventing misalignment during assembly and improving the fit accuracy between the ultrasonic transmission end 22 and the emitting surface. Furthermore, the protruding design of the first connector 23 from the mounting base 14 allows for direct sliding along the first anti-detachment groove 141 towards the patient when disassembling the drug carrier assembly 2, enabling quick separation of the drug carrier assembly 2 from the mounting base 14 without additional tools. This facilitates medicated pad replacement and enhances the convenience of clinical use.

[0071] Furthermore, the drug carrier assembly 2 includes a carrier seat 24 and a clamping seat 25; the two opposite ends of the carrier seat 24 are the ultrasonic transmission end 22 and the drug carrier end 21, respectively; each of the first insertion parts 23 is disposed on the outer peripheral surface of the carrier seat 24, and the carrier seat 24 is embedded in the limiting groove 13 as each of the first insertion parts 23 is inserted.

[0072] The outer peripheral surface of the mounting base 14 is provided with multiple second anti-dislodgement grooves 142. Each second anti-dislodgement groove 142 is arranged at intervals along the circumference of the mounting base 14 and passes through the end of the mounting base 14 facing the patient along the depth direction of the limiting groove 13.

[0073] The clamping seat 25 is slidably sleeved on the outer peripheral surface of the support seat 24. The clamping seat 25 is used to abut against the outer peripheral edge of the medicated pad applied to the drug support end 21. The clamping seat 25 is provided with a plurality of second insertion parts 251, each of the second insertion parts 251 being inserted into and engaged with the corresponding second anti-detachment groove 142. The clamping seat 25 abuts against the outer peripheral edge of the medicated pad synchronously with the insertion action of the second insertion parts 251.

[0074] By pressing the pressure seat 25 against the outer periphery of the medicated pad, the edge of the medicated pad is evenly pressed against the drug-carrying end 21. This not only prevents the edge of the medicated pad from lifting or shifting during treatment, but also keeps the entire medicated pad in close contact with the drug-carrying end 21, avoiding gaps between the medicated pad and the drug-carrying end 21 that could affect the transmission of ultrasonic energy. At the same time, the pressing force of the pressure seat 25 is applied to the carrier seat 24 through the medicated pad, further pushing the carrier seat 24 towards the direction of the ultrasonic wave generating structure 11 and strengthening the contact effect between the ultrasonic wave transmitting end 22 and the emitting surface of the ultrasonic wave generating structure 11. Through the insertion and engagement of the second insertion part 251 and the second anti-detachment groove 142, the pressure seat 25 is double-limited in both the circumferential and axial directions, ensuring that the pressure seat 25 can continuously and stably apply a uniform pressing force to the medicated pad. This prevents the medicated pad from falling off when the device moves or the patient's position changes, and also keeps the contact force on the carrier seat 24 constant.

[0075] The drug-carrying end 21 is preferably an arc-shaped surface, and the drug pad can be naturally laid on the arc-shaped drug-carrying end 21, so that the overall shape of the drug pad is pre-fitted to the natural curvature of human skin.

[0076] Furthermore, a plurality of second anti-detachment grooves 142 are provided in a one-to-one correspondence with a plurality of first anti-detachment grooves 141, and each second anti-detachment groove 142 is connected to the corresponding first anti-detachment groove 141.

[0077] The first insertion part 23 is provided with a card supply groove 231 on the side corresponding to the second anti-disengagement groove 142; the second insertion part 251 is provided with an elastic locking member 2511 on the side corresponding to the first anti-disengagement groove 141; the elastic locking member 2511 engages with the corresponding card supply groove 231 as the second insertion part 251 is inserted.

[0078] The limiting fit drive assembly 3 is assembled on the sealing seat 15 and is respectively connected to each of the first insertion parts 23 in a transmission manner.

[0079] Through the communication structure between the second anti-dislodgement groove 142 and the first anti-dislodgement groove 141, the second insertion part 251 can be inserted into the second anti-dislodgement groove 142 along the direction of the first anti-dislodgement groove 141 and engage with the first insertion part 23; through the engagement of the elastic engaging member 2511 with the engaging groove 231, the clamping seat 25 and the bearing seat 24 are linked and fixed, preventing them from separating during treatment; at the same time, the driving force of the limiting and fitting drive assembly 3 on the bearing seat 24 can be indirectly transmitted to the clamping seat 25, further enhancing the clamping effect of the clamping seat 25 on the medicated pad.

[0080] Furthermore, each of the first insertion portions 23 is provided with a force-receiving groove 232 and a clearance groove 233; each of the force-receiving grooves 232 extends radially through the corresponding first insertion portion 23 along the mounting base 14; the clearance groove 233 extends circumferentially along the mounting base 14 and passes through one side of the corresponding first insertion portion 23; the clearance groove 233 and the force-receiving groove 232 are arranged sequentially in the direction away from the patient and are interconnected.

[0081] The limiting and fitting drive assembly 3 includes a rotary seat 31, an elastic drive member 32, and a transmission seat 33; the rotary seat 31 is rotatably embedded in the end of the sealing seat 15 away from the external thread 151; the transmission seat 33 is movably sleeved on the outer peripheral surface of the sealing seat 15; the outer peripheral surface of the transmission seat 33 is provided with a force-applying part 331 corresponding to each of the force-receiving grooves 232, and the force-applying part 331 moves with the rotation of the transmission seat 33 and is embedded in the corresponding clearance groove 233;

[0082] The elastic drive member 32 is sleeved on the outer peripheral surface of the sealing seat 15, and the two ends of the elastic drive member 32 are respectively assembled to the rotary seat 31 and the transmission seat 33. The elastic drive member 32 is used to drive the transmission seat 33 to move away from the patient, so that each of the force-applying parts 331 is embedded in the corresponding force-receiving groove 232, so as to apply a contact force to the bearing seat 24 to keep the ultrasonic transmission end 22 and the emitting surface of the ultrasonic generation structure 11 in contact.

[0083] The clearance groove 233 provides a circumferential rotation channel for the force-applying part 331, allowing the force-applying part 331 to slide circumferentially into the end of the clearance groove 233 and align with the force-receiving groove 232. During assembly, medical personnel first press the transmission seat 33 towards the patient, aligning the force-applying part 331 on the transmission seat 33 with the clearance groove 233 on the first insertion part 23. During this process, the elastic drive member 32 is stretched and accumulates elastic tension. While maintaining the pressing state, the transmission seat 33 is rotated circumferentially, causing the force-applying part 331 to rotate into the clearance groove 233. Then, the transmission seat 33 is released, and the stretched elastic drive member 32 retracts, pulling the transmission seat 33 in a direction away from the patient, thus driving the force-applying part 331 to move in the opposite direction from the patient. 31 slides from the clearance groove 233 into the force receiving groove 232. The force applying part 331 abuts against the groove wall of the force receiving groove 232, converting the tension of the elastic drive member 32 into a continuous and stable abutting force, pushing the carrier seat 24 closer to the mounting seat 14, so that the ultrasonic transmission end 22 and the emitting surface of the ultrasonic generation structure 11 always remain in close contact. During treatment, the elastic drive member 32 can adaptively compensate for the gap and maintain a stable contact state. When disassembling, press the transmission seat 33 again towards the patient to make the force applying part 331 retract from the force receiving groove 232 to avoid the clearance groove 233. Rotate the transmission seat 33 in the opposite direction to make the force applying part 331 exit the clearance groove 233, and the drug carrier assembly 2 can be disassembled.

[0084] The elastic drive element 32 is preferably a cylindrical helical tension spring.

[0085] Furthermore, the transmission seat 33 is provided with multiple anti-torsion limiting rods 332 and multiple anti-slip teeth 333; the multiple anti-torsion limiting rods 332 extend in a direction away from the bearing seat 24 and are arranged at intervals along the circumference of the transmission seat 33; the rotary seat 31 is provided with multiple force-bearing through holes 311, and each anti-torsion limiting rod 332 is slidably inserted into the corresponding force-bearing through hole 311. The anti-torsion limiting rods 332 are used to drive the rotary seat 31 to rotate synchronously with the transmission seat 33; each anti-slip tooth 333 is arranged at the end of the transmission seat 33 away from the patient and is arranged at intervals along the circumference of the transmission seat 33.

[0086] By cooperating with the anti-torsion limiting rod 332 and the force-bearing through hole 311, the transmission seat 33 and the rotary seat 31 rotate synchronously, preventing relative circumferential misalignment between the transmission seat 33 and the rotary seat 31 when they rotate. This prevents the elastic drive member 32 from undergoing circumferential torsional deformation due to asynchronous rotation at both ends, ensuring that the elastic drive member 32 always provides stable tension only in the predetermined direction. At the same time, the anti-torsion limiting rod 332 can slide axially within the force-bearing through hole 311, guiding the pressing and resetting actions of the transmission seat 33. The anti-slip teeth 333 increase the friction on the surface of the transmission seat 33, making it easier for medical personnel to apply force and rotate stably, avoiding slippage during operation, and improving the convenience and reliability of the device.

[0087] In the description of this specification, references to terms such as "one embodiment," "some embodiments," "example," "specific example," or "some examples," etc., indicate that a specific feature, structure, material, or characteristic described in connection with that embodiment or example is included in at least one embodiment or example of this application. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. Moreover, without contradiction, those skilled in the art can combine and integrate the different embodiments or examples described in this specification, as well as the features of those different embodiments or examples.

[0088] Furthermore, the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include at least one of that feature. In the description of this application, "a plurality of" means two or more, unless otherwise explicitly specified.

[0089] The above description is merely a specific embodiment of this application, but the scope of protection of this application is not limited thereto. Any person skilled in the art can easily conceive of various variations or substitutions within the technical scope disclosed in this application, and these should all be included within the scope of protection of this application. Therefore, the scope of protection of this application should be determined by the scope of the claims.

Claims

1. A nephrology ultrasound-guided drug delivery device, characterized in that, include: The device body (1) is provided with an ultrasonic wave generating structure (11) for emitting ultrasonic waves toward the patient. A drug carrier assembly (2) is assembled on the device body (1); the end of the drug carrier assembly (2) facing the patient is a drug carrier end (21), which is used to install a medicated pad; the end of the drug carrier assembly (2) opposite to the drug carrier end (21) is an ultrasonic wave transmission end (22), which is in contact with the emitting surface of the ultrasonic wave generating structure (11), and is used to receive ultrasonic waves and transmit ultrasonic waves to the drug carrier end (21); A limiting fit driving component (3) is assembled on the device body (1) and is connected to the drug carrier component (2) in a transmission manner. The limiting fit driving component (3) is used to apply a driving force toward the ultrasonic wave generating structure (11) to the drug carrier component (2) so that the ultrasonic wave transmitting end (22) is in contact with the emitting surface of the ultrasonic wave generating structure (11).

2. The nephrology ultrasound transdermal drug delivery device according to claim 1, characterized in that, The device body (1) has an installation cavity (12) located at the end of the device body (1) facing the patient; the ultrasonic wave generating structure (11) is installed at the bottom of the installation cavity (12) and is used to emit multi-focal ultrasonic waves in the direction facing the patient. The device body (1) has a limiting groove (13) at the end facing the patient. The limiting groove (13) surrounds the outer periphery of the ultrasonic generating structure (11) along the circumference of the device body (1). The drug carrier component (2) is detachably embedded in the limiting groove (13). The ultrasonic transmitting end (22) is synchronously attached to the emitting surface of the ultrasonic generating structure (11) with the docking action of the drug carrier component (2).

3. The nephrology ultrasound transdermal drug delivery device according to claim 2, characterized in that, The outer wall of the limiting groove (13) is provided with a plurality of exhaust holes (131). Each exhaust hole (131) is arranged at intervals along the circumference of the limiting groove (13) and penetrates the outer wall of the limiting groove (13) and the inner wall of the limiting groove (13).

4. The nephrology ultrasound transdermal drug delivery device according to claim 2, characterized in that, The device body (1) includes a mounting base (14) and a sealing base (15); the mounting cavity (12) is opened in the mounting base (14) and passes through the end of the mounting base (14) away from the patient; the cavity wall of the mounting cavity (12) is provided with an internal thread (121); the limiting groove (13) is opened in the end of the mounting base (14) facing the patient; The bottom of the mounting cavity (12) is provided with a sealing element mounting groove (122), and the sealing element mounting groove (122) is arranged around the circumference of the mounting cavity (12); The outer circumferential surface of the sealing seat (15) is provided with an external thread (151), which is used to engage with the internal thread (121) of the mounting cavity (12) to seal the mounting cavity (12); the bottom end of the sealing seat (15) presses against the seal in the sealing mounting groove (122) simultaneously as the external thread (151) engages with the internal thread (121).

5. The nephrology ultrasound transdermal drug delivery device according to claim 4, characterized in that, The ultrasonic generating structure (11) has multiple ultrasonic array elements (111), each of which is arranged circumferentially and at intervals along the mounting cavity (12); each of the ultrasonic array elements (111) has multiple piezoelectric elements (1111), and the multiple piezoelectric elements (1111) of the same ultrasonic array element (111) are arranged radially and at intervals along the mounting cavity (12); among the multiple ultrasonic array elements (111), the multiple piezoelectric elements (1111) located at the same radial position in the mounting cavity (12) together form an ultrasonic focusing group; multiple ultrasonic focusing groups at different radial positions are respectively used to form ultrasonic focusing areas at corresponding depths in human tissue. The bottom end of the sealing seat (15) is provided with an excitation part (152) corresponding to each of the ultrasonic focusing groups. Each of the excitation parts (152) is assembled with the sealing seat (15) and the mounting seat (14) and is electrically connected to each of the piezoelectric array elements (1111) corresponding to the ultrasonic focusing group. The device body (1) is also provided with a control unit (16), which is mounted on the sealing seat (15) and is electrically connected to each of the excitation units (152).

6. The nephrology ultrasound transdermal drug delivery device according to claim 4, characterized in that, The outer peripheral surface of the mounting base (14) is provided with multiple first anti-detachment grooves (141). The multiple first anti-detachment grooves (141) are arranged at intervals along the circumference of the mounting base (14), and all of them penetrate the two ends of the mounting base (14) facing the patient and away from the patient along the depth direction of the limiting groove (13). The drug carrier assembly (2) is provided with a plurality of first plug-in portions (23), which are arranged at intervals along the circumference of the drug carrier assembly (2) and are plugged into the corresponding first anti-dislodgement groove (141), and protrude from the end of the mounting base (14) away from the patient; the drug carrier assembly (2) is embedded in the limiting groove (13) as each of the first plug-in portions (23) is plugged in.

7. The nephrology ultrasound transdermal drug delivery device according to claim 6, characterized in that, The drug carrier assembly (2) includes a carrier seat (24) and a clamping seat (25); the two opposite ends of the carrier seat (24) are the ultrasonic transmission end (22) and the drug carrier end (21), respectively; each of the first insertion parts (23) is provided on the outer peripheral surface of the carrier seat (24), and the carrier seat (24) is embedded in the limiting groove (13) as the first insertion parts (23) are inserted; The outer peripheral surface of the mounting base (14) is provided with multiple second anti-dislodgement grooves (142), each of the second anti-dislodgement grooves (142) is provided at intervals along the circumference of the mounting base (14), and all of them penetrate the end of the mounting base (14) facing the patient along the depth direction of the limiting groove (13). The clamping seat (25) is slidably sleeved on the outer peripheral surface of the support seat (24). The clamping seat (25) is used to abut against the outer periphery of the medicated pad applied to the drug support end (21). The clamping seat (25) is provided with a plurality of second insertion parts (251), each of the second insertion parts (251) being inserted into and engaged with the corresponding second anti-detachment groove (142). The clamping seat (25) abuts against the outer periphery of the medicated pad synchronously with the insertion action of the second insertion parts (251).

8. The nephrology ultrasound transdermal drug delivery device according to claim 7, characterized in that, A plurality of second anti-detachment grooves (142) are provided in a one-to-one correspondence with a plurality of first anti-detachment grooves (141), and each second anti-detachment groove (142) is connected to the corresponding first anti-detachment groove (141); The first insertion part (23) is provided with a card-feeding groove (231) on the side facing the second anti-disengagement groove (142); the second insertion part (251) is provided with an elastic locking member (2511) on the side facing the first anti-disengagement groove (141); the elastic locking member (2511) engages with the corresponding card-feeding groove (231) as the second insertion part (251) is inserted; The limiting fit drive assembly (3) is assembled on the sealing seat (15) and is connected to each of the first insertion parts (23) in a transmission manner.

9. A nephrology ultrasound transdermal drug delivery device according to claim 8, characterized in that, Each of the first insertion portions (23) is provided with a force-bearing groove (232) and a clearance groove (233); each of the force-bearing grooves (232) passes through the corresponding first insertion portion (23) radially along the mounting base (14); the clearance groove (233) extends circumferentially along the mounting base (14) and passes through one side of the corresponding first insertion portion (23); the clearance groove (233) and the force-bearing groove (232) are arranged sequentially in the direction away from the patient and are interconnected; The limiting fit drive assembly (3) includes a rotary seat (31), an elastic drive member (32), and a transmission seat (33); the rotary seat (31) is rotatably embedded in the end of the sealing seat (15) away from the external thread (151); the transmission seat (33) is movably sleeved on the outer peripheral surface of the sealing seat (15); the outer peripheral surface of the transmission seat (33) is provided with a force-applying part (331) corresponding to each of the force-receiving grooves (232), and the force-applying part (331) is embedded in the corresponding clearance groove (233) as the transmission seat (33) rotates; The elastic drive member (32) is sleeved on the outer peripheral surface of the sealing seat (15), and the two ends of the elastic drive member (32) are respectively assembled on the rotary seat (31) and the transmission seat (33). The elastic drive member (32) is used to drive the transmission seat (33) to move away from the patient, so that each of the force-applying parts (331) is embedded in the corresponding force-receiving groove (232) to apply a contact force to the bearing seat (24) to keep the ultrasonic transmission end (22) and the emitting surface of the ultrasonic generation structure (11) in contact.

10. A nephrology ultrasound transdermal drug delivery device according to claim 9, characterized in that, The transmission seat (33) is provided with multiple anti-torsion limiting rods (332) and multiple anti-slip teeth (333); the multiple anti-torsion limiting rods (332) all extend in a direction away from the bearing seat (24) and are arranged at intervals along the circumference of the transmission seat (33); the rotary seat (31) is provided with multiple force-bearing through holes (311) respectively, and each anti-torsion limiting rod (332) is slidably inserted into the corresponding force-bearing through hole (311). The anti-torsion limiting rods (332) are used to drive the rotary seat (31) to rotate synchronously with the transmission seat (33); each anti-slip tooth (333) is arranged at the end of the transmission seat (33) away from the patient and is arranged at intervals along the circumference of the transmission seat (33).

Images